Development of integrated microfluidic platform coupled with Surface-enhanced Raman Spectroscopy for diagnosis of COVID-19

Corona Virus Disease 19 (COVID-19) pandemic has created an alarming situation across the globe. Varieties of diagnostic protocols are being developed for the diagnosis of COVID-19. Many of these diagnostic protocols however, have limitations such as for example unacceptable no of false-positive and false-negative cases, particularly during the early stages of infection. At present, the real-time (quantitative) reverse transcriptase-polymerase chain reaction (RT-PCR) is considered the gold standard for COVID-19 diagnosis. However, RT-PCR based tests are complex, expensive, time consuming and involve pre-processing of samples. A swift, sensitive, inexpensive protocol for mass screening is urgently needed to contain this pandemic. There is urgent need to harness new powerful technologies for accurate detection not only of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) but also combating the emergence of pandemics of new viruses as well. To overcome the current challenges, the authors propose a diagnostic protocol based on surface-enhanced Raman Spectroscopy (SERS) coupled with microfluidic devices containing integrated microchannels functionalized either with vertically aligned Au/Ag coated carbon nanotubes or with disposable electrospun micro/nano-filter membranes. These devices have the potential to successfully trap viruses from diverse biological fluids/secretions including saliva, nasopharyngeal, tear etc. These can thus enrich the viral titre and enable accurate identification of the viruses from their respective Raman signatures. If the device is successfully developed and proven to detect target viruses, it would facilitate rapid screening of symptomatic as well as asymptomatic individuals of COVID-19. This would be a valuable diagnostic tool not only for mass screening of current COVID -19 pandemic but also in viral pandemic outbreaks of future.

[1]  Malik Peiris,et al.  Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures , 2020, The Lancet Respiratory Medicine.

[2]  Bhavya Sharma,et al.  In Vitro and In Vivo SERS Biosensing for Disease Diagnosis , 2018, Biosensors.

[3]  I. Albert,et al.  A rapid and label-free platform for virus capture and identification from clinical samples , 2019, Proceedings of the National Academy of Sciences.

[4]  Arti R. Hole,et al.  Raman spectroscopy‐based detection of RNA viruses in saliva: A preliminary report , 2020, Journal of biophotonics.

[5]  I. Albert,et al.  Tunable and label-free virus enrichment for ultrasensitive virus detection using carbon nanotube arrays , 2016, Science Advances.

[6]  Cynthia Liu,et al.  Assay Techniques and Test Development for COVID-19 Diagnosis , 2020, ACS central science.

[7]  J. Tong,et al.  Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS‐CoV‐2 infection , 2020, Journal of medical virology.

[8]  E. Duh,et al.  Title: ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection Short title: ACE2 and TMPRSS2 expression on the human ocular surface Authors: , 2020 .

[9]  S. Ghasemi,et al.  Genotype and phenotype of COVID-19: Their roles in pathogenesis , 2020, Journal of Microbiology, Immunology and Infection.

[10]  T. Tumpey,et al.  Ocular Tropism of Respiratory Viruses , 2013, Microbiology and Molecular Reviews.

[11]  A. Fine Recent trends. , 2003, Managed care quarterly.